HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon Q2

This article was originally published in The Rose Sheet

Executive Summary

Net revenue rose a lower-than-expected 6% to $1.9 bil. in the second quarter, impacted by decreasing beauty boutique sales in China and lower-than-anticipated growth in Central and Eastern Europe, firm reports during July 19 earnings call. Avon expected a 30% increase in China, but sales in the region fell 19% due to concerns of boutique owners over the resumption of direct selling, according to CEO Andrea Jung. Net income was up 41% to $28.6 mil., Avon adds. North American and U.S. sales declined 4% and 6% to $617.8 mil. and $527.6 mil., respectively. However, Avon will continue to support its brands in North America with a 50% increase in advertising spend, primarily to support new skin care innovations slated to launch in Q4, firm says...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013211

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel